AU2006272609A1 - Abl kinase inhibition - Google Patents
Abl kinase inhibition Download PDFInfo
- Publication number
- AU2006272609A1 AU2006272609A1 AU2006272609A AU2006272609A AU2006272609A1 AU 2006272609 A1 AU2006272609 A1 AU 2006272609A1 AU 2006272609 A AU2006272609 A AU 2006272609A AU 2006272609 A AU2006272609 A AU 2006272609A AU 2006272609 A1 AU2006272609 A1 AU 2006272609A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- abl
- patient
- kinase
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70277105P | 2005-07-26 | 2005-07-26 | |
| US60/702,771 | 2005-07-26 | ||
| US78516106P | 2006-03-23 | 2006-03-23 | |
| US60/785,161 | 2006-03-23 | ||
| US83025706P | 2006-07-12 | 2006-07-12 | |
| US60/830,257 | 2006-07-12 | ||
| PCT/US2006/028984 WO2007014250A2 (en) | 2005-07-26 | 2006-07-26 | Abl kinase inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2006272609A1 true AU2006272609A1 (en) | 2007-02-01 |
Family
ID=37683933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006272609A Abandoned AU2006272609A1 (en) | 2005-07-26 | 2006-07-26 | Abl kinase inhibition |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090298844A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1906967A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2009502937A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006272609A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2616517A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007014250A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007065124A2 (en) * | 2005-12-01 | 2007-06-07 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting complex karyotypes |
| EP2051737A2 (en) * | 2006-07-26 | 2009-04-29 | Merck & Co., Inc. | A novel lactic acid formulation of mk-0457 useful for the treatment of cancer |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| RS62649B1 (sr) | 2013-03-12 | 2021-12-31 | Vertex Pharma | Inhibitori dnk-pk |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2341133A1 (en) * | 2001-10-05 | 2011-07-06 | Novartis AG | Mutated Abl kinase domains |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| BRPI0515012A (pt) * | 2004-08-13 | 2008-07-01 | Genentech Inc | substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso |
-
2006
- 2006-07-26 EP EP06800350A patent/EP1906967A4/en not_active Withdrawn
- 2006-07-26 CA CA002616517A patent/CA2616517A1/en not_active Abandoned
- 2006-07-26 WO PCT/US2006/028984 patent/WO2007014250A2/en not_active Ceased
- 2006-07-26 AU AU2006272609A patent/AU2006272609A1/en not_active Abandoned
- 2006-07-26 JP JP2008524094A patent/JP2009502937A/ja active Pending
- 2006-07-26 US US11/989,300 patent/US20090298844A1/en not_active Abandoned
-
2012
- 2012-05-29 JP JP2012122081A patent/JP2012158616A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007014250A8 (en) | 2008-02-21 |
| JP2009502937A (ja) | 2009-01-29 |
| EP1906967A2 (en) | 2008-04-09 |
| EP1906967A4 (en) | 2010-07-28 |
| CA2616517A1 (en) | 2007-02-01 |
| WO2007014250A3 (en) | 2007-06-28 |
| US20090298844A1 (en) | 2009-12-03 |
| JP2012158616A (ja) | 2012-08-23 |
| WO2007014250A2 (en) | 2007-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2383269B1 (de) | Substituierte Dihydropyrazolone zur Behandlung von Herz-Kreislauf-Erkrankungen | |
| EP3782998B1 (en) | Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof | |
| JP2023512040A (ja) | 化合物及びその使用 | |
| JP2012158616A (ja) | Ablキナーゼ阻害 | |
| HUE026381T2 (en) | Kinase inhibitor picolinamide derivatives | |
| EP2097404A1 (de) | Substituierte dipyridyl-dihydropyrazolone und ihre verwendung | |
| JP2021510717A (ja) | キナーゼ活性を阻害するためのジフェニルアミノピリミジン系化合物 | |
| DE102008020113A1 (de) | Substituierte Dihydropyrazolone und ihre Verwendung | |
| US20210238148A1 (en) | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | |
| EP2640718B1 (de) | Substituiertes natrium-1h-pyrazol-5-olat | |
| JP6404944B2 (ja) | ホスファチジルイノシトール3−キナーゼ阻害薬としてのピラジン誘導体 | |
| US11713306B2 (en) | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | |
| EP4587429A1 (en) | Substituted oxoisoindolinyl piperidine-2,6-dione compounds | |
| CN101222850A (zh) | 治疗对药物有抗性的癌症的方法 | |
| AU2017326029B2 (en) | Deuterated 3-(4,5-substituted pyrimidinamine) phenyl derivatives and applications thereof | |
| US11919899B2 (en) | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability | |
| US20230144901A1 (en) | Sortilin antagonists for use in the treatment of diabetic retinopathy | |
| JP2022548230A (ja) | 新規化合物及び方法 | |
| US12421221B2 (en) | Heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same | |
| JP7289961B1 (ja) | がん治療のための併用療法 | |
| EP4737453A1 (en) | Novel selenophene derivatives | |
| WO2023200427A1 (en) | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative crystal form, salt crystal form, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |